Hengrui's PD-1 camrelizumab priced at RMB 19,800 a shot



China-based Jiangsu Hengrui Medicine Co., Ltd’s recently approved programmed death-1 (PD-1) monoclonal antibody (mAb) camrelizumab has officially been priced. A notice from Hengrui subsidiary Suzhou Shengdiya Biopharmaceutical Co., Ltd, the drug’s manufacturer revealed the mAb will be launched at a price of RMB 19,800 (USD 2,863) per 200mg bottle.

Camrelizumab became the third domestically produced PD-1 drug to gain market approval from the National Medical Products Administration (NMPA) in May, indicated as a treatment for relapsed or refractory classic Hodgkin's lymphoma (cHL) in patients treated with at least two lines of systemic chemotherapy. The indication exactly matches that of Innovent Biologics Inc.’s sintilimab (Tyvyt). According to the notice, Shengdiya Biopharma also received Good Manufacturing Practice (GMP) approval for camrelizumab from Jiangsu Food and Drug Administration (JSFDA) bureau on June 10, meaning all hurdles have been cleared ahead of launch.

GBI research reveals that Hengrui is wasting no time in targeting other indications, with camrelizumab already filed for approval in hepatocellular carcinoma (HCC). That filing has received priority review status, and is also notable as it is made on the back of Phase II trial data only meaning that Hengrui is looking for a conditional approval as the first PD-1 drug for HCC in China. According to Hengrui, data from a Phase III trial of camrelizumab in esophageal cancer has also already been sent to the NMPA.


PD-1 mAbs approved for market in China

Manufacturer

Brand name (molecule name)

Approval date

Indication(s)

Price

Bristol-Myers Squibb

Opdivo (nivolumab)

2018-06-15

Non-small cell lung cancer

RMB 9,260 (100mg/10ml)

RMB 4,591 (40mg/4ml)

Merck Sharp & Dohme

Keytruda (pembrolizumab)

2018-07-20

Melanoma

RMB 17,918 (100mg/4ml)

Shanghai Junshi Biosciences

Tuoyi (toripalimab)

2018-12-17

Melanoma

RMB 7,200 (240mg/6ml)

Innovent Biologics, Inc.

Tyvyt (sintilimab)

2018-12-24

R/R cHL

RMB 7,838
(100mg/10ml)

Jiangsu Hengrui Medicine

Camrelizumab

2019-05-29


R/R cHL


RMB 19,800 (299mg)


Reference:

Related news
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
China-based biotech BeiGene Ltd (Nasdaq: BGNE; HKEX:06160) released data updates on two pipeline candidates at this week’s European Hematology Association (EHA) meeting.
  • 1560739210247
  • China
  • Drug
Jiangsu Hengrui Pharmaceutical Co., Ltd, (SSE: 600276) announced that its PD-1 antibody injection camrelibizumab (SHR-1210) combined with pemetrexed plus carboplatin has been approved by the National Medical Products Administration (NMPA) to start a clinical trial in advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
  • 1559792379500
  • China
  • Drug
China-based biotechs Innovent Biologics Inc., (HKEX.1801) and Ascentage Pharma provided poster updates of clinical trial data at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO).
  • 1559628389344
  • China
  • Drug
Brazil's National Health Surveillance Agency (ANVISA) has approved Bristol-Myers Squibb (BMS)’s programmed death-1 (PD-1) inhibitor Opdivo (nivolumab) as an adjuvant therapy against melanoma to reduce the risk of recurrence.
Recent news
Nelson Mussolini, head of Brazil’s Industry Syndicate of Pharmaceutical Products (SINDUSFARMA) and member of the National Health Council, this week voiced his position against the government’s control of drug prices and the high tax rates.
The Center for State Control of Drugs and Medical Devices (CECMED) last week cleared Catalonia (Spain)-based Laboratorio Estedi’s Ursobilane (ursodeoxycholic acid) for the Cuba market, GBI analysis reveals.
According to GBI analysis, Peru’s General Directorate of Medicines, Supplies and Drugs (DIGEMID) this week granted marketing authorization to Japan-based Otsuka Pharmaceutical’s drug-resistant tuberculosis (TB) treatment Deltyba (delamanid).
China-based Sino Biopharmaceutical Ltd (HKEX.01177) announced the signing of a joint venture (JV) agreement between its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd, and Akeso Biopharma Inc​.
A team of Chinese scientists led by Professor Ma Xiong, from Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine (Renji Hospital)'s gastroenterology department, has uncovered the characteristics of intestinal flora in patients with autoimmune hepatitis (AIH), according to the hospital.
  • 1560834410023
  • China
  • R&D
China-based biotechs Tot Biopharm Co., Ltd, and Shanghai Junshi Biosciences Co., Ltd, (HKX.1877) agreed to pair Tot's TAB008, a biosimilar of Roche’s anti-VEGF monoclonal antibody (mAb) bevacizumab (Avastin), in combination with Junshi Bio’s toripalimab (JS001), an innovative recombinant human programmed death-1 (PD-1) monoclonal antibody (mAb).
Colombia’s National Food and Drug Surveillance Institute (INVIMA) this week issued marketing approval to Johnson & Johnson (J&J) subsidiary Janssen’s oral cancer drug Erleada (apalutamide).